Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart, Inc. (OTCQX: VXRT) is a clinical-stage biotechnology company developing oral recombinant vaccines delivered as pills, and its news flow reflects progress across multiple vaccine programs and corporate developments. The company regularly issues updates on its clinical trials for oral pill vaccine candidates targeting coronavirus, norovirus and influenza, as well as a therapeutic HPV vaccine candidate that it identifies as its first immune-oncology program.
Readers following Vaxart news can expect detailed reports on clinical data from its oral vaccine platform. For example, the company has announced Phase 1 results for a bivalent norovirus pill vaccine in lactating women, describing safety, tolerability and increases in norovirus-specific IgA in serum and breast milk, along with evidence of norovirus-specific IgA in infant stool. Vaxart has also highlighted data from second-generation norovirus constructs showing stronger blocking antibody responses and robust fecal IgA increases, and has presented these findings at scientific conferences such as the International Calicivirus Conference, World Vaccine Congress and IDWeek.
Vaxart’s news also covers its COVID-19 oral pill vaccine program, including enrollment and follow-up in a large Phase 2b trial funded under a Project NextGen/BARDA contract, and regulatory and funding updates such as a stop work order that delimited certain activities while maintaining support for follow-up of enrolled participants. In addition, the company has reported on an exclusive, worldwide license and collaboration agreement with Dynavax Technologies Corporation for its oral COVID-19 vaccine candidate, outlining the structure of upfront payments, an equity investment, and potential milestones and royalties.
Beyond clinical and partnership news, Vaxart issues releases on corporate actions, including stock listing changes, governance matters and capital markets events such as conference presentations and investor calls. Investors and observers can use this news feed to track the evolution of Vaxart’s oral vaccine platform, key trial readouts, collaboration milestones and changes in its trading venue and cost management initiatives.
Vaxart, Inc. (Nasdaq: VXRT) has announced the granting of inducement equity awards to two new non-executive employees. The awards, approved by the Compensation Committee on August 26, 2024, include:
- 21,500 stock options vesting over 4 years
- 10,750 restricted stock units vesting over 4 years
These awards were granted under the Vaxart, Inc. 2024 Inducement Award Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The plan is exclusively used for granting equity awards to new employees as an inducement to join Vaxart.
Vaxart (NASDAQ: VXRT) has published preclinical data in Vaccines journal, showcasing the potential of its mucosal vaccine technology for treating HPV-related cervical dysplasia. The study demonstrated that Vaxart's HPV vaccine constructs can:
1. Stimulate specific T cell immune responses against HPV16 E6 and E7 proteins
2. Reduce tumor size in an animal model of HPV-related tumorigenesis
3. Increase survival in mice with HPV-expressing tumors
The results suggest that Vaxart's platform could enable a non-invasive treatment for HPV-related cervical dysplasia, potentially preventing progression to cervical cancer. The vaccine's ease of administration and room temperature stability could address global inequities in HPV-related cancer treatment.
Vaxart, Inc. (NASDAQ: VXRT) reported its Q2 2024 financial results and provided a business update. Key highlights include:
1. BARDA awarded Vaxart up to $453 million for a Phase 2b trial of its oral COVID-19 vaccine.
2. The company plans to initiate the 10,000-subject Phase 2b trial in H2 2024, pending FDA alignment.
3. Vaxart is in discussions with the FDA regarding norovirus vaccine data and potential next steps.
4. Q2 2024 financial results: $62.6 million in cash and investments, $6.4 million in revenue, and a net loss of $16.5 million ($0.09 per share).
5. The company received a $64.7 million BARDA payment post-Q2, extending cash runway into 2026.
Vaxart (NASDAQ: VXRT) has announced it will provide a business update and report financial results for the second quarter ended June 30, 2024, after the market close on Thursday, August 8, 2024. The company's senior management team will host a conference call on the same day at 4:30 p.m. ET. Investors can access the call via webcast or by phone using specific dial-in numbers. Written questions can be submitted in advance to ir@vaxart.com. A replay of the webcast will be available on Vaxart's website following the event.
Vaxart (VXRT) announced a significant business update, revealing an extended cash runway into 2026, bolstered by a $453 million Project NextGen award from BARDA and a $40 million financing round. The funds will advance its oral pill vaccine platform, targeting COVID-19 and norovirus. A 10,000-subject Phase 2b study for their COVID-19 vaccine is set to begin in summer 2024, with interim efficacy analysis expected in Q1 2025. Feedback from the FDA for the norovirus vaccine is anticipated by mid-2024, potentially leading to further studies. Vaxart is also progressing in early-stage programs for influenza and HPV, driven by recent bird flu outbreaks.
Vaxart (Nasdaq: VXRT) has announced an underwritten offering of 50 million shares of its common stock at $0.80 per share, a premium over the last closing price of $0.75 per share. The offering is expected to generate gross proceeds of $40 million, before deducting underwriting discounts, commissions, and other expenses. The offering is scheduled to close around June 17, 2024, subject to customary conditions. Oppenheimer & Co. is the sole bookrunner for the offering. The shares are being offered under an effective shelf registration previously filed with the SEC, and additional details are available in the prospectus supplement to be filed with the SEC.
Vaxart (VXRT) has received a BARDA-funded Project NextGen award valued up to $453 million for a Phase 2b study of its oral COVID-19 vaccine candidate. The study will involve 10,000 subjects and compare the oral vaccine to an FDA-approved mRNA vaccine. Preliminary enrollment is expected by summer 2024, with interim efficacy results as early as Q1 2025. Initial funding of $65.7 million will support study preparations, with an additional $387.2 million provided based on study progress. Previous trials showed the vaccine's effectiveness against various SARS-CoV-2 variants and strong immune responses.
On May 23, 2024, Vaxart announced inducement equity awards granted on May 17, 2024, to a new non-executive employee. The awards include an option to purchase 15,000 shares of Vaxart’s common stock, vesting over four years, and 7,500 restricted stock units (RSUs), vesting 25% annually for four years. These awards were issued under Vaxart's 2024 Inducement Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4). This plan is specifically used to attract new employees not previously with Vaxart or rejoining after a bona fide period of non-employment.
Vaxart (Nasdaq: VXRT) reported positive Phase 1 results for its oral pill norovirus vaccine in lactating mothers. The company plans to start a Phase 2b study for its XBB COVID-19 vaccine by Q2 2024. Vaxart aims to meet the FDA in mid-2024 to discuss its norovirus program. Financially, Vaxart posted a Q1 2024 net loss of $24.4M, improved from $25.1M in Q1 2023. Revenues rose to $2.2M from $0.7M in Q1 2023, primarily due to BARDA contract work. Cash reserves are $36.7M, sufficient until late Q4 2024. R&D expenses decreased to $19.0M, while G&A expenses increased to $7.2M.
Vaxart, Inc. (NASDAQ: VXRT) will host a conference call on May 13, 2024, to provide a business update and report financial results for the first quarter ending March 31, 2024. Investors can access the conference call online or by phone, and submit questions in advance. A replay will be available on the company's website.